|  Drug Name  | MOA  | Experiment  | Method  | Parameter  | Mean  | Unit  | 
| ---- | --- | --- | --- | --- | --- | --- | 
|  H1H15211P  | Signal Transduction Modulators;Anti-Spike Protein (Middle East Respiratory Syndrome Coronavirus)  | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO  | Luciferine/luciferase assay  | IC-50  | 4.74E-11  | M  | 
|  90-F1  | Anti-Spike Protein (Middle East Respiratory Syndrome Coronavirus)  | Spike Glycoprotein (MERS-CoV) affinity, IN VITRO  | Surface plasmon resonance assay  | Kd  | 7.20E-11  | M  | 
|  MERS-4V2  | Anti-Spike Protein (Middle East Respiratory Syndrome Coronavirus)  | Spike Glycoprotein (MERS-CoV) affinity, IN VITRO  | ELISA assay  | Kd  | 7.32E-10  | M  | 
|  Chloroquine  |   | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  |   | IC-50  | 8.00E-10  | M  | 
|  Nafamostat mesilate  | Tryptase Inhibitors  | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO  | Vero cells (TMPRSS2-expressing) transfected with MERS  | IC-50  | 1.00E-09  | M  | 
|  Silvestrol  | Eukaryotic Initiation Factor 4A (eIF4A) Inhibitors;Apoptosis Inducers  | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO  | Plaque assay  | IC-50  | 1.30E-09  | M  | 
|  BanLec  |   | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO  | Cytopathicity assay  | IC-50  | 3.99E-09  | M  | 
|  Remdesivir  | Nucleobindin-1 (NUCB1) Inhibitors  | Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO  | Viral replication assay  | IC-50  | 1.00E-08  | M  | 
|  SR9EK1  |   | Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO  | Viral replication assay  | IC-90  | 1.25E-08  | M  | 
|  Lycorine  |   | Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO  | Dye assay  | IC-50  | 1.57E-08  | M  | 
|  Noscapine  | Tubulin Polymerization Inhibitors;Apoptosis Inducers;Antimitotic Drugs  | Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO  | Cytopathicity assay  | IC-90  | 2.20E-08  | g/l  | 
|  6',6'-Difluoroaristeromycin  | S-Adenosyl-L-Homocysteine Hydrolase Inhibitors  | Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO  | Plaque assay  | MIC  | 1.00E-07  | M  | 
|  Azithromycin  | Nonsense Mutation Suppressors;50S Ribosomal Protein Inhibitors  | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO  | Luciferine/luciferase assay  | IC-50  | 1.00E-07  | M  | 
|  IIS  | Viral Fusion Inhibitors  | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO  | HEK293 human embryonic kidney cells transfected with MERS/enhanced green fluorescent protein  | IC-50  | 1.00E-07  | M  | 
|  Niclosamide  | Cytochrome P450 CYP1A2 Inhibitors;Quorum Sensing (Pseudomonas aeruginosa) Inhibitors;Neuropeptide Y4 (NPY Y4) Receptor Positive Allosteric Modulators;Autophagy Inducers;Wnt Signaling Inhibitors  | Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO  | Cytopathicity assay  | IC-50  | 1.00E-07  | M  | 
|  Promazine  | Signal Transduction Modulators;Dopamine Receptor Antagonists  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  | Cytopathicity assay  | MIC  | 1.00E-07  | M  | 
|  SR9EK2  |   | Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO  | Viral replication assay  | IC-90  | 1.08E-07  | M  | 
|  IIQ  | Viral Fusion Inhibitors  | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO  | HEK293 human embryonic kidney cells transfected with MERS/enhanced green fluorescent protein  | IC-50  | 1.10E-07  | M  | 
|  TG-0205221  | 3C-Like Protease (SARS-CoV) Inhibitors  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  | Plaque assay  | IC-50  | 1.40E-07  | M  | 
|  Emetine  | Platelet-Derived Growth Factor (PDGF) Inhibitors;Signal Transduction Modulators;Angiogenesis Inhibitors  | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO  | Cytopathicity assay  | IC-50  | 1.50E-07  | M  | 
|  GC-376  | 3C-Like Protease (Norovirus) Inhibitors  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  | Viral replication assay  | IC-50  | 1.50E-07  | M  | 
|  Mycophenolic acid sodium salt  | Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors  | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO  | Cytopathicity assay  | IC-50  | 1.70E-07  | M  | 
|  JMF-1521  |   | Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO  | Cytopathicity assay  | IC-50  | 1.80E-07  | M  | 
|  Cycloheximide  | Signal Transduction Modulators;Glycogen Synthase Kinase 3 beta (GSK-3beta; tau Protein Kinase I) Inhibitors;Ferroptosis Inhibitors  | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO  | Cytopathicity assay  | IC-50  | 1.90E-07  | M  | 
|  GC-373  | 3C-Like Protease (Norovirus) Inhibitors  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  | Viral replication assay  | IC-50  | 2.00E-07  | M  | 
|  Mycophenolate mofetil  | Hydroxycarboxylic Acid Receptor 2 (HCAR2; NIACR1; GPR109A) Agonists;Signal Transduction Modulators;Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  | Viral replication assay  | IC-50  | 2.30E-07  | M  | 
|  N-3  | 3C-Like Protease (NL63 Coronavirus) (HCoV-NL63) Inhibitors  | Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO  | MCA-Ala-Val-Leu-Gln-Ser-Gly-Phe-Arg-lys(Dnp)-lys-NH2 as substrate  | Ki  | 2.30E-07  | M  | 
|  P-21S8  |   | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO  | HEK293 human embryonic kidney cells transfected with MERS/enhanced green fluorescent protein  | IC-50  | 2.60E-07  | M  | 
|  Rupintrivir  | HRV 3C Protease Inhibitors  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  | Viral replication assay  | IC-50  | 3.00E-07  | M  | 
|  Chloroquine phosphate  | Apoptosis Inducers  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  | Cytopathicity assay  | IC-50  | 3.06E-07  | M  | 
|  GRL-0667  | Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors  | Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO  | Arg-Leu-Arg-Gly-Gly-7-amino-4-methylcoumarin as substrate  | IC-50  | 3.20E-07  | M  | 
|  P-21S10  |   | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO  | HEK293 human embryonic kidney cells transfected with MERS/enhanced green fluorescent protein  | IC-50  | 3.30E-07  | M  | 
|  Sinefungin  | Coactivator Associated Arginine Methyltransferase 1 (CARM1; PRMT4) Inhibitors;Histone-Lysine N-Methyltransferase SETD7 (SET7/9) Inhibitors;Protein-L-Isoaspartate(D-Aspartate) O-Methyltransferase (PCMT1; PIMT) Inhibitors;Epigenetic Modifier Modulators  | Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO  |   | IC-50  | 3.83E-07  | M  | 
|  KIN-269  | Interferon Regulatory Factor 3 (IRF-3) Activators  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  |   | IC-50  | 3.90E-07  | M  | 
|  Gemcitabine hydrochloride  | Ribonucleoside-Diphosphate Reductase Inhibitors;Pyrimidine Antagonists  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  | Cytopathicity assay  | IC-50  | 4.40E-07  | M  | 
|  GRL-0617  | Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors  | Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO  | Arg-Leu-Arg-Gly-Gly-7-amino-4-methylcoumarin as substrate  | IC-50  | 5.60E-07  | M  | 
|  HR2P  | Viral Fusion Inhibitors  | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO  | Cytopathicity assay  | IC-50  | 6.00E-07  | M  | 
|  M-34  | Anti-Spike Protein (Middle East Respiratory Syndrome Coronavirus)  | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO  |   | IC-50  | 6.00E-07  | g/l  | 
|  Betulonic acid  | Lysosomal alpha-Glucosidase (GAA) Inhibitors;E3 Ubiquitin-Protein Ligase Inhibitors  | Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO  | Cytopathicity assay  | IC-50  | 6.30E-07  | M  | 
|  HR2P-M2  | Viral Fusion Inhibitors  | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO  | Luciferine/luciferase assay  | IC-50  | 6.40E-07  | M  | 
|  KIN-1160  | Interferon Regulatory Factor 3 (IRF-3) Activators  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  |   | IC-50  | 6.91E-07  | M  | 
|  Tanshinone I  | Signal Transduction Modulators;AP-1 Transcription Factor Complex Inhibitors;Aryl Hydrocarbon Receptor (AhR) Ligands  | Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO  | Ubiquitin-7-amino-4-methylcoumarin as substrate  | IC-50  | 7.00E-07  | M  | 
|  [N-MeIle4]-cyclosporin  | Cyclophilin Inhibitors;Mitochondrial Permeability Transition (MPT) Inhibitors  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  | RNA assay  | IC-50  | 8.00E-07  | M  | 
|  Alisporivir  | P-Glycoprotein (MDR-1; ABCB1) Inhibitors;Cyclophilin Inhibitors  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  | RNA assay  | IC-50  | 8.00E-07  | M  | 
|  Ciclosporin  | Cyclophilin D Inhibitors;Signal Transduction Modulators;Serine/Threonine-Protein Phosphatase 2B (PPP3CC; PP2Bgamma; Calcineurin) Inhibitors;INS Expression Inhibitors  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  | RNA assay  | IC-50  | 9.00E-07  | M  | 
|  Geldanamycin  | Signal Transduction Modulators;Heat Shock Protein 90 (Hsp90) Inhibitors  | Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO  |   | IC-50  | 9.10E-07  | M  | 
|  NSC-158362  |   | Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO  | Viral replication assay  | IC-50  | 1.00E-06  | M  | 
|  (-)-Savinin  | Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Drugs Acting on Tumor Necrosis Factor (TNF) Receptors  | Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO  | Cytopathicity assay  | IC-50  | 1.13E-06  | M  | 
|  Dihydrotan  | Hypoxia Inducible Factor 1-alpha (HIF-1alpha) Inhibitors;Immune Checkpoint Inhibitors;Indoleamine 2,3-dioxygenase 1 (IDO1; IDO) Inhibitors;Acetylcholinesterase (AChE) Inhibitors;Nitric Oxide (NO) Production Inhibitors  | Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO  | Ubiquitin-7-amino-4-methylcoumarin as substrate  | IC-50  | 1.20E-06  | M  | 
|  SR9EK3  |   | Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO  | Viral replication assay  | IC-90  | 1.23E-06  | M  | 
|  Monensin A sodium salt  |   | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  |   | IC-50  | 1.25E-06  | M  | 
|  Ferruginol  | 3C-Like Protease (SARS-CoV) Inhibitors;Lipid Peroxidation Inhibitors;Antioxidants;Apoptosis Inducers  | Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO  | Cytopathicity assay  | IC-50  | 1.39E-06  | M  | 
|  Ferroquine  |   | Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO  |   | IC-50  | 1.40E-06  | M  | 
|  Apigenin  | NMDA Receptor Antagonists;Cytochrome P450 CYP1A2 Inhibitors;Ornithine Decarboxylase Inhibitors;Drugs Targeting on Quorum Sensing Signaling;Signal Transduction Modulators;MAO-A Inhibitors;Xanthine Oxidase Inhibitors;Apoptosis Inducers;Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) Inhibitors;VEGF Expression Inhibitors;Angiogenesis Inhibitors;GABA(A) Receptor Antagonists;Nitric Oxide (NO) Production Inhibitors  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  |   | IC-50  | 1.70E-06  | M  | 
|  Ganciclovir  | DNA Polymerase Inhibitors  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  | Dye assay (MTS)  | IC-50  | 1.70E-06  | g/l  | 
|  3,4-Dihydroxyamphetamine  |   | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  | Dye assay (MTS)  | IC-50  | 2.00E-06  | g/l  | 
|  Phenazopyridine hydrochloride  |   | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  | Viral replication assay  | IC-50  | 2.02E-06  | M  | 
|  Chlorpyrifos  |   | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  | Viral replication assay  | IC-50  | 2.27E-06  | M  | 
|  Chlorpromazine  | Signal Transduction Modulators;Dopamine D2 Receptor (DRD2) Antagonists;Kinesin-Like Spindle Protein KIF11 (KSP; Eg5) Inhibitors;Antimitotic Drugs  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  | Gene reporter assay  | IC-50  | 2.50E-06  | M  | 
|  Hirsutenone  | Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;LDL Antioxidants;Signal Transduction Modulators;Antiinflammatory Drugs;Free Radical Scavengers;Nitric Oxide (NO) Production Inhibitors  | Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO  | Ubiquitin-7-amino-4-methylcoumarin as substrate  | IC-50  | 3.00E-06  | M  | 
|  Fluphenazine hydrochloride  | Signal Transduction Modulators;Nicotinic alpha7 Receptor Ligands;Dopamine D2 Receptor (DRD2) Antagonists  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  |   | IC-50  | 3.23E-06  | M  | 
|  K-22  |   | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  | Cytopathicity assay  | IC-50  | 3.30E-06  | M  | 
|  Triflupromazine hydrochloride  | Signal Transduction Modulators;Nicotinic alpha7 Receptor Ligands  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  |   | IC-50  | 3.32E-06  | M  | 
|  Astemizole  | Histamine H1 Receptor Antagonists;Signal Transduction Modulators  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  |   | IC-50  | 3.48E-06  | M  | 
|  Papyriflavonol A  | Signal Transduction Modulators;Phospholipase A2 (PLA2) Inhibitors  | Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO  | Fluorescent assay  | IC-50  | 3.70E-06  | M  | 
|  Berberine iodide  | DNA-Intercalating Drugs;Insulin Secretagogues;Signal Transduction Modulators;AMP-Activated Protein Kinase (AMPK) Activators;Prolyl Endopeptidase (prolyl oligopeptidase; POP) Inhibitors;Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors;Potassium Channel Blockers;Acetylcholinesterase (AChE) Inhibitors;LDL-Receptor Up-Regulators;Reverse Transcriptase/Ribonuclease H (Viral) Inhibitors;Protein Tyrosine Phosphatase PTP-1B Inhibitors  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  |   | IC-50  | 3.80E-06  | M  | 
|  Loperamide hydrochloride  | Signal Transduction Modulators;mu-Opioid Receptor Agonists;Atrial Natriuretic Peptide B (NPR2; Guanylate Cyclase B) Receptor Antagonists  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  | Gene reporter assay  | IC-50  | 4.00E-06  | M  | 
|  Retro-94  |   | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO  |   | IC-50  | 4.10E-06  | M  | 
|  Psoralidin  | Estrogen Receptor (ER) beta Agonists;Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Estrogen Receptor (ER) alpha Agonists;5-Lipoxygenase Inhibitors;Signal Transduction Modulators;Tyrosine-Protein Phosphatase Non-Receptor Type 1 (PTPN1; PTP-1B) Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors;Caspase Activators;Apoptosis Inducers  | Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO  | Arg-Leu-Arg-Gly-Gly-7-amino-4-methylcoumarin as substrate  | IC-50  | 4.20E-06  | M  | 
|  Quinacrine hydrochloride  | Secretory Phospholipase A2 (sPLA2) Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Signal Transduction Modulators;Cytokine Production Inhibitors;TP53 Expression Enhancers  | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO  |   | IC-50  | 4.20E-06  | M  | 
|  KIN-101  | Interferon Regulatory Factor 3 (IRF-3) Activators  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  |   | IC-50  | 4.50E-06  | M  | 
|  Saquinavir  | HIV Protease Inhibitors  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  | Cytopathicity assay  | MIC  | 4.66E-06  | M  | 
|  24F2-2  | Anti-Spike Protein (Middle East Respiratory Syndrome Coronavirus)  | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO  | Luciferine/luciferase assay  | IC-50  | 4.89E-06  | g/l  | 
|  Imatinib mesylate  | Tyrosine-Protein Kinase ABL1 Inhibitors;Bcr-Abl (Bcr-Abl1) Kinase Inhibitors;PDGFRalpha Inhibitors;PDGFRbeta Inhibitors;Signal Transduction Modulators;Breast Cancer-Resistant Protein (BCRP; ABCG2) Inhibitors;KIT (C-KIT) Inhibitors;CSF1R (c-FMS) Inhibitors;Apoptosis Inducers;Angiogenesis Inhibitors  | Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO  | RNA assay  | MIC  | 5.00E-06  | M  | 
|  S377-588-Fc  |   | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, EX VIVO  | ELISA assay  | MED  | 5.00E-06  | g  | 
|  Tomentin E  | Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors  | Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO  | Arg-Leu-Arg-Gly-Gly-7-amino-4-methylcoumarin as substrate  | IC-50  | 5.00E-06  | M  | 
|  Dasatinib  | Tyrosine-Protein Kinase Lck (LCK) Inhibitors;Tyrosine-Protein Kinase ABL1 Inhibitors;Bcr-Abl (Bcr-Abl1) Kinase Inhibitors;Signal Transduction Modulators;Lyn Kinase Inhibitors;PDGFRbeta Inhibitors;Anti-LRPPRC (Leucine-Rich PPR Motif-Containing Protein, Mitochondrial);KIT (C-KIT) Inhibitors;Ephrin type-A receptor 2 (EPHA2) Receptor Inhibitors;Discoidin Domain-Containing Receptor 2 (DDR2) Inhibitors;Discoidin Domain-Containing Receptor 1 (DDR1) Inhibitors;Bruton's Tyrosine Kinase (BTK) Inhibitors;Tyrosine-Protein Kinase CSK Inhibitors;Angiogenesis Inhibitors;Tyrosine Kinase Inhibitors;Yes Kinase Inhibitors;Fyn Kinase Inhibitors  | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO  | Cytopathicity assay  | IC-50  | 5.47E-06  | M  | 
|  Lopinavir  | HIV Protease Inhibitors  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  | Viral replication assay  | IC-50  | 5.60E-06  | M  | 
|  Curcumin  | Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;CCND1 Expression Inhibitors;Glucose-6-Phosphatase Inhibitors;P-Glycoprotein (MDR-1; ABCB1) Inhibitors;HIV Integrase Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Signal Transduction Modulators;Antiinflammatory Drugs;Histone N-Acetyltransferase (HAT) Inhibitors;Microtubule-Associated Protein Tau (PHF-tau; MAPT) Aggregation Inhibitors;AP-1 Transcription Factor Complex Inhibitors;DNA Methyltransferase 1 (DNMT1) Inhibitors;Apoptosis Inducers;Prostaglandin G/H Synthase 1 (PTGS1; COX-1) Inhibitors;Antioxidants;Angiogenesis Inhibitors;EGFR Expression Inhibitors;Cell Division Protein FtsZ (Bacterial) Inhibitors;Free Radical Scavengers;Lipoxygenase Inhibitors;Wnt Signaling Inhibitors  | Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO  | Arg-Leu-Arg-Gly-Gly-7-amino-4-methylcoumarin as substrate  | IC-50  | 5.70E-06  | M  | 
|  RH-01  | 3C-Like Protease (NL63 Coronavirus) (HCoV-NL63) Inhibitors;3C-Like Protease (EMC Coronavirus) (HCoV-EMC) Inhibitors  | Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO  |   | IC-50  | 5.72E-06  | M  | 
|  Tiotixene  |   | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  |   | IC-50  | 5.74E-06  | M  | 
|  SG-85  | 3C-Like Protease (NL63 Coronavirus) (HCoV-NL63) Inhibitors;3C Protease (Enterovirus 71) Inhibitors;3C-Like Protease (EMC Coronavirus) (HCoV-EMC) Inhibitors  | Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO  |   | IC-50  | 6.06E-06  | M  | 
|  Amodiaquine hydrochloride  |   | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO  | Cytopathicity assay  | IC-50  | 6.21E-06  | M  | 
|  Tacrolimus  | Signal Transduction Modulators;Serine/Threonine-Protein Phosphatase 2B (PPP3CC; PP2Bgamma; Calcineurin) Inhibitors;FK506-Binding Protein 12 (Peptidyl-Prolyl Cis-Trans Isomerase FKBP12) Inhibitors  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  | RNA assay  | IC-50  | 6.60E-06  | M  | 
|  Quercetin  | Catechol-O-Methyl Transferase (COMT) Inhibitors;Drugs Targeting on Quorum Sensing Signaling;Tyrosine-Protein Phosphatase Non-Receptor Type 1 (PTPN1; PTP-1B) Inhibitors;MAO-A Inhibitors;NAD-Dependent Protein Deacetylase Sirtuin-1 (SIRT1) Activators;Signal Transduction Modulators;Lysosomal alpha-Glucosidase (GAA) Inhibitors;Xanthine Oxidase Inhibitors;EGFR (HER1; erbB1) Inhibitors;Cytokine Production Inhibitors;Antioxidants;Steryl-Sulfatase (STS) Inhibitors;Aldose Reductase Inhibitors;Sodium Channel Protein Type 5 Subunit alpha (Nav1.5) Channel Blockers;Free Radical Scavengers;Epigenetic Modifier Modulators;Wnt Signaling Inhibitors  | Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO  | Uncompetitive inhibition mode  | Ki  | 7.00E-06  | M  | 
|  Mucroporin-M1  | Cell Membrane Disrupting Agents  | Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO  | Plaque assay  | IC-50  | 7.12E-06  | M  | 
|  Isobavachalcone  | Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Steroid 5alpha-Reductase Inhibitors;Drugs Targeting Beta-Amyloid;Signal Transduction Modulators;Autophagy Inducers;Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors;Antioxidants  | Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO  | Arg-Leu-Arg-Gly-Gly-7-amino-4-methylcoumarin as substrate  | IC-50  | 7.30E-06  | M  | 
|  Tamoxifen citrate  | Selective Estrogen Receptor Modulators (SERM);Signal Transduction Modulators;Protein Kinase C (PKC) Inhibitors  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  |   | IC-50  | 7.46E-06  | M  | 
|  Promethazine hydrochloride  | Histamine H1 Receptor Antagonists;Signal Transduction Modulators  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  |   | IC-50  | 7.48E-06  | M  | 
|  Bavachinin  | Hypoxia Inducible Factor 1-alpha (HIF-1alpha) Inhibitors;beta-Amyloid (Abeta) Aggregation Inhibitors;MAO-B Inhibitors;Signal Transduction Modulators;PPAR Agonists;Apoptosis Inducers;Antioxidants;beta-Secretase 1 (BACE1) Inhibitors;Antiamyloidogenic Agents  | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO  |   | IC-50  | 7.90E-06  | M  | 
|  Broussochalcone A  | Signal Transduction Modulators;Protein Kinase C (PKC) Inhibitors  | Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO  | Uncompetitive inhibition mode  | Ki  | 8.00E-06  | M  | 
|  Nelfinavir mesilate  | HIV-1 Protease Inhibitors;Proteasome Inhibitors  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  | Cytopathicity assay  | IC-50  | 8.19E-06  | M  | 
|  Hydroxychloroquine sulfate  | Palmitoyl-Protein Thioesterase 1 (PPT1) Inhibitors;Autophagy Inhibitors  | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO  | Cytopathicity assay  | IC-50  | 8.28E-06  | M  | 
|  Clomipramine hydrochloride  | Signal Transduction Modulators;Serotonin Transporter (SERT) Inhibitors  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  |   | IC-50  | 8.79E-06  | M  | 
|  HP-083  |   | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  | Cytopathicity assay  | IC-50  | 8.80E-06  | M  | 
|  SSYA-10-001  |   | Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO  | Viral replication assay  | IC-50  | 8.95E-06  | M  | 
|  Cryptotanshinone  | Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors;Signal Transduction Modulators;Antiinflammatory Drugs;Antioxidants;Aldose Reductase Inhibitors;Angiogenesis Inhibitors;Acetylcholinesterase (AChE) Inhibitors;Nitric Oxide (NO) Production Inhibitors  | Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO  | Arg-Leu-Arg-Gly-Gly-7-amino-4-methylcoumarin as substrate  | Ki  | 9.00E-06  | M  | 
|  Tioguanine  | Purine Antagonists  | Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO  | Competitive inhibition mode  | Ki  | 9.10E-06  | M  | 
|  Methyltanshinonate  |   | Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO  | Arg-Leu-Arg-Gly-Gly-7-amino-4-methylcoumarin as substrate  | Ki  | 9.70E-06  | M  | 
|  Efavirenz  | Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors  | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO  | Cytopathicity assay  | MIC  | 9.90E-06  | M  | 
|  Ribavirin  | Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;Equilibrative Nucleoside Transporter ENT1 Inhibitors  | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO  | Cytopathicity assay  | IC-50  | 9.99E-06  | M  | 
